Adoptive cell therapy (ACT) is rapidly migrating from bench to clinical therapy for hematological malignancies. Recently, a new subtype of memory T cells, stem cell memory T (T SCM ) cells, was shown to be one of the most favorable subsets for ACT. T SCM has high self-renewal capacity and is associated with superior T cell engraftment, persistence, and antitumor immunity. In this review, we focused on the characteristics of antigen-specific T SCM cells and discussed their potential for immunotherapy targeting hematological malignancies.
Introduction
T cell immunodeficiencies have been observed in patients with hematological disorders [1] . These deficiencies lead to the expansion of malignant clones and are thought to play an important role in tumorigenesis [2] [3] [4] [5] . To design an effective approach for recovering T cell immunity, particularly antigen-specific T cell immunity, it is necessary to accurately evaluate the T cell immune status at either the molecular or cellular level, including characteristics such as recent thymic output function, number of naive T cells, diversity in the T cell receptor (TCR) repertoire, and tumor antigen-specific cytotoxicity T cell clones [6] [7] [8] [9] . More recently, stem cell memory T (T SCM ) cells have been described as a new immune biomarker for evaluating long-term memory T cell immune reconstitution, which is an important index after hematopoietic stem cell transplantation (HSCT) [10] [11] [12] .
T SCM cells have been shown to be able to differentiate into central memory T cells (T CM ), effector memory (T EM ), and terminal effector T cells (T TE ).
Adaptive immunity is characterized by the ability to form long-lived immunological memory. Memory T cells develop when antigen-specific naive CD4 + or CD8 + T cells become activated upon antigen exposure and subsequently undergo proliferative expansion and differentiation [13, 14] . Therefore, efficient and persistent immune memory is essential for long-term protection against infections and malignancies. Memory T cells play a critical role in maintaining this immune defense [15] . T SCM cells are considered as an important immune marker for the repopulating T cell pool and immune reconstitution which is associated with favorable clinical outcome after HSCT [16] . T SCM cell research may support the advances in biomarker research, diagnosis, and therapy for hematological malignancies [17] [18] [19] [20] . Moreover, T SCM cell research may be important for understanding and influencing diverse chronic immune reactions, including graft-versus-host disease (GVHD) [21] .
T SCM cell characteristics

Memory T cells (including CD4
+ and CD8 + memory T cells) include several subtypes: stem cell memory (T SCM ), central memory (T CM ), transitional memory (T TM ) (described only in CD4 + memory T cells), effector memory (T EM ), and terminal effector (T TE ) T cells [16, 22] . T SCM cells were first observed in a murine model of GVHD by Zhang et al., who reported a new subset of post-mitotic CD44 lo CD62L hi CD8
+ T cells expressing Sca-1 (stem cell antigen 1), CD122, and Bcl-2. This population of T cells was able to generate and sustain all allogeneic T cell subsets in GVHD reactions. These alloreactive CD8 + T cells were demonstrated to have enhanced self-renewal capacity and multipotency. These cells are capable of differentiating into T CM , T EM , and T TE cells [14, 21] . In humans, an example came from the identification of a population of naive yellow fever (YF)-specific CD8 + T cells after vaccination. These cells were stably maintained for more than 25 years and were capable of ex vivo self-renewal. Indepth analysis of markers and genome-wide mRNA profiling have shown that these cells are distinct from genuine naive cells from unvaccinated donors and resemble the recently described stem cell-like memory subset T SCM [23] . Moreover, epigenetic analysis has also revealed that histone modifications and gene expression signatures could distinguish T SCM from other CD8 + T cell subsets [24] . Increasing data have supported the notion that the human T SCM subset is a clearly distinct subset in between the naive T cell (T N ) and T CM subsets. Human T SCM cells have been described as a long-lived memory T cell population which are CD45RO Table 1 . T SCM cells express increased levels of CD95, IL-2Rβ, CXCR3, and LFA-1 and exhibit numerous functional attributes distinct from memory cells. However, human T SCM cells constitute only approximately 2-4 % of the total CD4 + and CD8 + T cell population in the periphery and can be identified by polychromatic flow cytometry based on the simultaneous expression of several naive markers together with the memory marker CD95 [25] . A linear T cell differentiation model and the minimum set of markers used for identifying and sorting T SCM are depicted in Fig. 1 [25] .
Self-renewing memory T cells may be regulated by shared signaling pathways such as those involved in hematopoietic stem cells or memory B cells. The Wnt-β-catenin pathway is an evolutionarily conserved pathway that regulates hematopoietic stem cell self-renewal and multipotency by limiting stem cell proliferation and differentiation. Similarly, a key role for Wnt signaling during the maintenance of "stemness" in CD8
+ T SCM cells was demonstrated by Gattinoni et [11, 26, 27] . In addition, antigen-specific T SCM cells were shown to preferentially reside in the lymph nodes (LNs) and less so in the spleen and bone marrow [28] .
There are numerous factors that act as modulators regulating the maturation and activation of CD8 + T cells, for example, suppressor of cytokine signaling (SOCS) is one of the key modulators [29] . Moreover, it has been reported that activation of naive T cells with anti-CD3 and anti-CD28 antibody-conjugated beads in the presence of low doses of IL-7 and IL-15 promotes the generation of CD45RA
+ T SCM cells [30] .
Antigen-specific T SCM
It is well known that antigen-specific T cells are crucial components for antitumor or antivirus immunity in patients with hematological malignancies, particularly in patients after HSCT. It is possible that the number of antigen-specific T SCM cells may be the determining factor of immunity. However, there have been few reports on antigen-specific T SCM cells. Low frequency of these cells limits detailed characterization. For example, <1 % of total human T cells are defined as CD8 + CD45RA + CCR7 + CD127 + CD95 + viral-specific T SCM cells. Human CMV-specific T SCM cells can be detected at frequencies similar to those observed in other subsets, with frequency around ∼1/10,000 T cells [31, 32] .
Antigen-specific T SCM cells represent a long-lasting component of the cellular immune response to viruses and tumor-associated antigens (TAAs). For virus-specific T SCM cells, research has first focused on human immunodeficiency virus type 1 (HIV-1)-specific CD8 + T SCM cells. It is known that HIV-specific CD8 + T cells can influence HIV-1 disease progression during untreated HIV-1 infections, and recent data have shown that HIV-1-specific CD8 + T SCM cells are detectable in all stages of HIV-1 infection. These cells were found to be increased in number in patients receiving suppressive antiretroviral therapy when compared with those untreated patients [33] . It was found that CD4 + T SCM cells were susceptible to HIV infection; thus, HIV-1 virus may exploit the stem cell characteristics of cellular immune memory T cells and lead to long-term viral persistence [34] . Similar findings were demonstrated in a study of human T cell leukemia virus type 1 (HTLV-1)-infected CD4 + T SCM cells in patients with adult T cell leukemia (ATL). This report first demonstrated an association between T cell malignancy and T SCM cells. T SCM cells from ATL patients were capable of sustaining themselves in a less proliferative mode, yet they were able to differentiate into other memory T cell − "+" positive expression, "−" negative expression, T N naive T cell, T SCM stem cell memory T cell, T CM central memory T cell, T EM effector memory T cell, T TE terminal effector T cell populations during the rapidly propagating phase. These cells have been identified at the hierarchical apex capable of reconstituting identical ATL clones [35] . A decrease in the infection of CD4 + T SCM cells was found to preserve CD4 + T cell homeostasis and prevents disease progression despite significant viremia in both HIV-1 and HTLV-1 infections [36] .
T SCM cells may play a major role in specific antitumor response and long-term immune surveillance directed against tumors [17, 37, 38] . In addition, T SCM cells have been proposed to be one of the key determinants of immune memory. It may be interesting to monitor the level of T SCM cells and its significance for immune reconstitution and prognosis of patients with hematological malignancies before and after therapy, particularly HSCT. There have been only a few studies on TAA-specific T SCM cells. Recently, dynamic changes of T SCM cells were longitudinally tracked in patients who underwent haploidentical HSCT. These studies demonstrated that donor-derived T SCM cells were highly enriched early after HSCT. T SCM cells can differentiate directly from naive precursors infused in the grafts. Through T cell receptor (TCR) gene analysis, T SCM cells have been found to have diversification in immune memory after allogeneic HSCT [10] . It was also demonstrated that the level of T SCM cells may be used to evaluate immune reconstitution in patients who received posttransplant cyclophosphamide (pt-Cy) for GVHD prophylaxis. Similarly, donor-derived T SCM cells were found to be the most abundant circulating T cell population in the early days following haploidentical HSCT and pt-Cy. These donor-derived T SCM cells preceded the expansion of effector cells. Antigen-specific T SCM cells generated detectable recall responses; thus, it has been proposed to explore T SCM cells derived from donor naive precursor cells in the clinical setting to overcome immunodeficiency [12] . With the ability to expand and differentiate into effectors capable of mediating potent xenogeneic GVHD in immunodeficient mice, these donor naive precursor-derived T SCM cells were noted to be superior to other memory lymphocytes. Furthermore, genemodified T SCM cells were found to be the only T cell subset capable of expanding and mediating GVHD in serial transplantations [30] . These findings indicate negative aspects of T SCM cells for clinical application.
The potential of T SCM cells in immunotherapy for hematological malignancies
T SCM cells may be a novel and critical therapeutic resource because these cells have the potential to serve as a stable cellular vehicle. Two gene therapy clinical trials with gene-corrected hematopoietic stem cells provided a glimpse into this possibility. Long-term in vivo T cell reconstitution was characterized in these trials. Specifically, the investigators traced the fate of greater than 1700 individual T cell clones in patients who underwent gene therapy. The studies demonstrated that the T SCM cells persisted and preserved their precursor potential in humans for up to 12 years after the infusion of genecorrected stem cells [39] . The demonstration of the safe, functional, and decade-long survival of the engineered T SCM cells in humans sets the stage for their clinical application. Since T SCM cells were shown to be capable of reconstituting the full repertoire of memory and effector T cells after HSCT, it is particularly attractive to use them for adoptive immunotherapies. T SCM cells might overcome current limitations, such as inefficient T cell engraftment, poor persistence, and inability to mediate prolonged immune attacks [10] [11] [12] 40] .
Even though potent antitumor activity of T SCM cells was demonstrated in preclinical animal tumor models [26, 27] , it is currently not feasible to treat patients with naturally occurring T SCM cells because it is a scarce and Fig. 1 Schematic model for T cell differentiation. Upon activation, naive T cells differentiate into various memory and effector cells. Self-renewal capacity, multipotency, and proliferation potential decrease upon differentiation. The expression of CD45R0, CCR7, CD28, and CD95 markers changes during T cell differentiation from T N to T TE. The minimum set of canonical markers can be used to identify the five major subsets of T cells. T N naive T cell, T SCM stem cell memory T cell, T CM central memory T cell, T EM effector memory T cell, T TE terminal effector T cell small proportion of circulating lymphocytes. Therefore, strategies that can generate, expand, and enable the redirection of T SCM cells against cancer cells need to be defined. Cieri and colleagues have recently described that a large number of T SCM cells were generated by priming T cells with low doses of IL-7 and IL-15. It is therefore possible to generate, expand, and genetically engineer T SCM cells in vitro from naive precursors. Furthermore, the in vitro-generated T SCM cells displayed enhanced proliferative capacity upon adoptive transfer into immunodeficient mice, a finding consistent with those using naturally occurring T SCM cells [11, 30] . T SCM cells were also expanded from naive precursors by inhibiting Akt signaling during ex vivo priming and expansion. The Akt-inhibited minor histocompatibility antigen (MiHA)-specific CD8 + T cells had superior expansion capacity in vitro and induced superior antitumor activity in multiple myeloma-bearing immunodeficient mice. These findings provided a rationale for clinically exploiting ex vivo-generated, Akt-inhibited, MiHA-specific CD8 + T cells or TAA-specific CD8 + T cells for adoptive immunotherapy [41, 42] . Schmueck-Henneresse et al. also described a simplified culture protocol allowing for fast expansion of virus-specific T SCM cells from a mixed T N /T SCM pool of peripheral blood lymphocytes. This may be the basis for novel cell therapeutic options for life-threatening viral infections [31] . Among the known memory T cell subpopulations, the T SCM cell subset has profound implications for the design and development of effective vaccines as well as T cell-based therapies [13, 26, 28] . As immunotherapy plays increasingly important roles in cancer management, further exploration of T SCM cells and their regulation may facilitate clinical development of humoral (monoclonal antibodies and inhibitors of B cell receptor signaling) and cellular (CART) immunotherapies [40, [43] [44] [45] [46] [47] .
Conclusions and future perspectives
T SCM cells have the capacities of self-renewal and differentiation into various memory/effector subsets. These cells can lead to superior immune reconstitution. The identification of human T SCM cells is directly relevant for evaluating life-long cellular immune status, immune reconstitution after allogeneic HSCT, and design of vaccines and T cell immunotherapy. However, it remains unclear at this time whether the number of T SCM cells may be used as a standard biomarker for immune reconstitution after HSCT. In addition, the low number of T SCM cells in circulating lymphocytes is also limiting their application [11] . Strategies for in vitro and in vivo isolation and generation of highly effective antitumor T SCM cells are under intensive investigation.
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